别名 EFNB2、EPH-related receptor tyrosine kinase ligand 5、ephrin B2 + [10] |
简介 Cell surface transmembrane ligand for Eph receptors, a family of receptor tyrosine kinases which are crucial for migration, repulsion and adhesion during neuronal, vascular and epithelial development. Binds promiscuously Eph receptors residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Binds to receptor tyrosine kinase including EPHA4, EPHA3 and EPHB4. Together with EPHB4 plays a central role in heart morphogenesis and angiogenesis through regulation of cell adhesion and cell migration. EPHB4-mediated forward signaling controls cellular repulsion and segregation from EFNB2-expressing cells. May play a role in constraining the orientation of longitudinally projecting axons.
(Microbial infection) Acts as a receptor for Hendra virus and Nipah virus. |
靶点 |
作用机制 EFNB2 inhibitors |
在研机构 |
原研机构 |
在研适应症 |
非在研适应症- |
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
作用机制 EFNB2 inhibitors [+1] |
在研机构- |
在研适应症- |
非在研适应症 |
最高研发阶段终止 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
开始日期2024-07-31 |
申办/合作机构 |
开始日期2024-07-10 |
申办/合作机构 Mediar Therapeutics, Inc.初创企业 [+1] |